Overview of Long-term Follow-up from MonumenTAL-1

EP: 1.Long-Term Follow-up Overview: MajesTEC-1 and MagnetisMM-3 Recent Data

EP: 2.Adverse Event Management with BCMA Therapy

EP: 3.GPRC5D Therapy: Unique Challenges in Adverse Event Management

Now Viewing

EP: 4.Overview of Long-term Follow-up from MonumenTAL-1

EP: 5.Overview of Other GPRC5D Therapy Clinical Trials

EP: 6.Administration and Dosing Management

EP: 7.Clinical Perspective on AE Tolerance

EP: 8.Clinical Experience in Managing AEs in GPRC5D Therapy

EP: 9.Management and Supportive Care for CRS and ICANS in GPRC5D Therapy

EP: 10.Insights on REMS Programs and Strategies for Effective Patient Care

EP: 11.Clinical Scenario: AE Management in a Patient with R/R MM on GPRC5D Therapy

EP: 12.Adverse Event Management Strategies in GPRC5D Therapy

EP: 13.Clinical Scenario: AE Management for Bispecific Therapy in R/R MM

Video content above is prompted by the following:

• Focusing on long-term follow-up data from MonumenTAL-1, describe the unique toxicities seen with talquetamab, namely nail-related, skin-related, and oral-related toxicities.